Keyphrases
Glucose-dependent Insulinotropic Polypeptide
100%
Glucagon-like
91%
Healthy Individuals
48%
A1 Receptor
39%
Bone Resorption
32%
Randomized Placebo-controlled Trial
30%
Gut-bone Axis
29%
Type 2 Diabetic Patients
29%
Metabolic Effects
29%
Intravenous Alcohol
29%
Ethanol Infusion
29%
Glucos
29%
Alcohol Administration
29%
Placebo
27%
Exendin (9-39)
25%
Bone Homeostasis
22%
Gallbladder Motility
17%
Receptor Antagonism
17%
Incretin Hormones
16%
Meal Tolerance Test
16%
Diabetes
14%
Dasiglucagon
14%
Post-bariatric Hypoglycemia
14%
Structured Summaries
14%
Receptor Activation
14%
Potential Therapeutics
14%
Therapeutic Implications
14%
Gastric Bypass
14%
Acarbose
14%
Blood Lipids
14%
Oral Alcohol Administration
14%
Inflammation Markers
14%
Glucose-dependent Insulinotropic Polypeptide Receptor
13%
Oral Glucose Tolerance Test
13%
Receptor Antagonist
12%
Hypoglycemia
12%
Polypeptide 1
9%
Insulin Secretion
9%
Osseous
9%
Glucose Excursion
8%
Glucagon
8%
Safety Events
8%
Type 2 Diabetes Mellitus (T2DM)
7%
Postprandial Glucose
7%
C-peptide
7%
Enteroendocrine
7%
Gallbladder Volume
7%
Bone Formation
6%
Tirzepatide
5%
Fibroblast Growth Factor 21 (FGF21)
5%
Medicine and Dentistry
Gastric Inhibitory Polypeptide
54%
Placebo
42%
Osteolysis
38%
Gut
30%
Patient with Type 2 Diabetes
29%
Glucagon Like Peptide 1
27%
Homeostasis
23%
Glucagon Like Peptide 1 Receptor
19%
Gastric Bypass Surgery
14%
Gastric Bypass
14%
Controlled Clinical Trial
14%
Hypoglycemia
14%
Dasiglucagon
14%
Diabetes
14%
Acarbose
14%
Glucagon Like Peptide 2
13%
Incretin
12%
Test Meal
12%
Infusion
12%
Receptor
10%
Oral Glucose Tolerance Test
9%
Exendin 9
9%
Maturity Onset Diabetes of the Young
9%
Ossification
8%
Glucagon-Like Peptide-1 Agonist
5%
Pharmacology, Toxicology and Pharmaceutical Science
Gastric Inhibitory Polypeptide
60%
Glucagon-Like Peptide 1 Receptor
34%
Placebo
34%
Non Insulin Dependent Diabetes Mellitus
30%
Glucagon-Like Peptide-1
21%
Exendin 9
18%
Acarbose
14%
Controlled Clinical Trial
14%
Incretin
11%
Gastric Inhibitory Polypeptide Receptor
8%
Receptor Antagonist
8%
Tirzepatide
5%
